Novel insights into the pathophysiology of nonalcoholic fatty liver disease

Seminars in Liver Disease

Volumn 30, Issue 4, 2010, Pages 391-401

  Feldstein, Ariel E ^a,b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

apoptosis; free fatty acids; Lipotoxicity; nonalcoholic fatty liver disease; steatohepatitis

Indexed keywords

ADIPONECTIN; CHOLESTEROL; FATTY ACID; LIPID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR RISK; CELL DEATH; DISEASE ASSOCIATION; HEREDITY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID STORAGE; LIVER CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UNITED STATES;

ADIPOSE TISSUE; ANIMALS; CYTOKINES; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MACROPHAGES; MITOGEN-ACTIVATED PROTEIN KINASE 8; OBESITY; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958183243     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0030-1267539     Document Type: Review

References (113)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002 346 (16) 1221-1231
2. Wieckowska A, Feldstein A E. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr 2005 17 (5) 636-641
3. Brunt E M., Janney C G., Di Bisceglie A M., Neuschwander-Tetri B A., Bacon B R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999 94 (9) 2467-2474
4. Adams L A., Lymp J F., St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 129 (1) 113-121
5. Ekstedt M, Franzén L E., Mathiesen U L. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006 44 (4) 865-873
6. Browning J D., Horton J D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004 114 (2) 147-152
7. Donnelly K L., Smith C I., Schwarzenberg S J., Jessurun J, Boldt M D., Parks E J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005 115 (5) 1343-1351
8. Bieghs V, Wouters K, van Gorp P J. et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 2010 138 (7) 2477-2486, 2486, e1e3
9. Zhou J, Febbraio M, Wada T et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008 134 (2) 556-567
10. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008 118 (3) 829-838
11. Clark J M., Brancati F L., Diehl A M. Nonalcoholic fatty liver disease. Gastroenterology 2002 122 (6) 1649-1657
12. Tilg H, Moschen A R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008 19 (10) 371-379
13. Shoelson S E., Lee J, Goldfine A B. Inflammation and insulin resistance. J Clin Invest 2006 116 (7) 1793-1801
14. Wellen K E., Hotamisligil G S. Inflammation, stress, and diabetes. J Clin Invest 2005 115 (5) 1111-1119
15. Tilg H, Moschen A R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008 14 (3-4) 222-231
16. Weisberg S P., McCann D, Desai M, Rosenbaum M, Leibel R L., Ferrante A Jr.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003 112 (12) 1796-1808
17. Weisberg S P., Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006 116 (1) 115-124
18. Hevener A L., Olefsky J M., Reichart D et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 2007 117 (6) 1658-1669
19. Lumeng C N., Bodzin J L., Saltiel A R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007 117 (1) 175-184
20. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002 420 (6913) 333-336
21. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil G S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A 2006 103 (28) 10741-10746
22. Aguirre V, Uchida T, Yenush L, Davis R, White M F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000 275 (12) 9047-9054
23. Sabio G, Das M, Mora A et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008 322 (5907) 1539-1543
24. Kim J Y., van de Wall E, Laplante M et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007 117 (9) 2621-2637
25. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007 293 (4) E1118-E1128
26. Pang C, Gao Z, Yin J, Zhang J, Jia W, Ye J. Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity. Am J Physiol Endocrinol Metab 2008 295 (2) E313-E322
27. Lauber K, Bohn E, Kröber S M. et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003 113 (6) 717-730
28. Strissel K J., Stancheva Z, Miyoshi H et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007 56 (12) 2910-2918
29. Murano I, Barbatelli G, Parisani V et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008 49 (7) 1562-1568
30. Cinti S, Mitchell G, Barbatelli G et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005 46 (11) 2347-2355
31. Kroemer G, Galluzzi L, Vandenabeele P et al, Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009 16 (1) 3-11
32. Alkhouri N, Gornicka A, Berk M P. et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem 2010 285 (5) 3428-3438
33. Guicciardi M E., Gores G J. Life and death by death receptors. FASEB J 2009 23 (6) 1625-1637
34. Wueest S, Rapold R A., Schumann D M. et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J Clin Invest 2010 120 (1) 191-202
35. Li P, Lu M, Nguyen M T. et al. Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J Biol Chem 2010 285 (20) 15333-15345
36. Day C P., James O F. Steatohepatitis: a tale of two hits? Gastroenterology 1998 114 (4) 842-845
37. Clouston A D., Powell E E. Nonalcoholic fatty liver disease: is all the fat bad? Intern Med J 2004 34 (4) 187-191
38. Monetti M, Levin M C., Watt M J. et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007 6 (1) 69-78
39. Koliwad S K., Streeper R S., Monetti M et al. DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. J Clin Invest 2010 120 (3) 756-767
40. Amaro A, Fabbrini E, Kars M et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010 139 (1) 149-153
41. Day C P. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis 2004 8 (3) 673-691, xi
42. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008 40 (12) 1461-1465
43. He S, McPhaul C, Li J Z. et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010 285 (9) 6706-6715
44. Petersen K F., Dufour S, Hariri A et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010 362 (12) 1082-1089
45. Alkhouri N, Dixon L J., Feldstein A E. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 2009 3 (4) 445-451
46. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta 2010 1801 (3) 299-310
47. Yamaguchi K, Yang L, McCall S et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007 45 (6) 1366-1374
48. Li Z Z., Berk M, McIntyre T M., Feldstein A E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 2009 284 (9) 5637-5644
49. Garcia-Ruiz C, Mari M, Colell A et al. Mitochondrial cholesterol in health and disease. Histol Histopathol 2009 24 (1) 117-132
50. Marí M, Colell A, Morales A et al. Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 2008 134 (5) 1507-1520
51. Marí M, Caballero F, Colell A et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006 4 (3) 185-198
52. Puri P, Baillie R A., Wiest M M. et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007 46 (4) 1081-1090
53. Duncan R E., El-Sohemy A, Archer M C. Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development. Mol Nutr Food Res 2005 49 (2) 93-100
54. Duncan R E., El-Sohemy A, Archer M C. Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin. Cancer Lett 2005 224 (2) 221-228
55. Caballero F, Fernández A, De Lacy A M., Fernández-Checa J C., Caballería J, García-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 2009 50 (4) 789-796
56. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003 37 (2) 343-350
57. Feldstein A E., Canbay A, Guicciardi M E., Higuchi H, Bronk S F., Gores G J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003 39 (6) 978-983
58. Tomita K, Tamiya G, Ando S et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006 55 (3) 415-424
59. Xu A, Wang Y, Keshaw H, Xu L Y., Lam K S., Cooper G J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003 112 (1) 91-100
60. Crespo J, Cayón A, Fernández-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001 34 (6) 1158-1163
61. Hui J M., Hodge A, Farrell G C., Kench J G., Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004 40 (1) 46-54
62. Musso G, Gambino R, Durazzo M et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005 42 (5) 1175-1183
63. Abiru S, Migita K, Maeda Y et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006 26 (1) 39-45
64. Kugelmas M, Hill D B., Vivian B, Marsano L, McClain C J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003 38 (2) 413-419
65. Feldstein A E., Werneburg N W., Canbay A et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004 40 (1) 185-194
66. Feldstein A E., Werneburg N W., Li Z, Bronk S F., Gores G J. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 2006 290 (6) G1339-G1346
67. Li Z, Berk M, McIntyre T M., Gores G J., Feldstein A E. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008 47 (5) 1495-1503
68. Shimomura I, Shimano H, Korn B S., Bashmakov Y, Horton J D. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J Biol Chem 1998 273 (52) 35299-35306
69. Shimomura I, Bashmakov Y, Horton J D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999 274 (42) 30028-30032
70. Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood) 2007 232 (5) 614-621
71. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005 54 (1) 117-121 (Pubitemid 40007229)
72. Moschen A R., Molnar C, Wolf A M. et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009 51 (4) 765-777
73. Lagathu C, Bastard J P., Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003 311 (2) 372-379
74. Klover P J., Zimmers T A., Koniaris L G., Mooney R A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003 52 (11) 2784-2789
75. Senn J J., Klover P J., Nowak I A. et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003 278 (16) 13740-13746
76. Pradhan A D., Manson J E., Rifai N, Buring J E., Ridker P M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001 286 (3) 327-334
77. Haukeland J W., Damås J K., Konopski Z et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006 44 (6) 1167-1174
78. Cai D, Yuan M, Frantz D F. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005 11 (2) 183-190
79. Wieckowska A, Papouchado B G., Li Z, Lopez R, Zein N N., Feldstein A E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008 103 (6) 1372-1379
80. El-Assal O, Hong F, Kim W H., Radaeva S, Gao B. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004 1 (3) 205-211
81. Cressman D E., Greenbaum L E., DeAngelis R A. et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996 274 (5291) 1379-1383
82. Jin X, Zimmers T A., Perez E A., Pierce R H., Zhang Z, Koniaris L G. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 2006 43 (3) 474-484
83. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology 2006 44 (6) 1487-1501
84. Milner K L., van der Poorten D, Xu A et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009 49 (6) 1926-1934
85. Schroeder F, Jolly C A., Cho T H., Frolov A. Fatty acid binding protein isoforms: structure and function. Chem Phys Lipids 1998 92 (1) 1-25
86. Hui X, Li H, Zhou Z et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem 2010 285 (14) 10273-10280
87. Wieckowska A, McCullough A J., Feldstein A E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007 46 (2) 582-589
88. Feldstein A E., Canbay A, Angulo P et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003 125 (2) 437-443
89. Feldstein A E., Gores G J. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005 10 3093-3099
90. Barreyro F J., Kobayashi S, Bronk S F., Werneburg N W., Malhi H, Gores G J. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem 2007 282 (37) 27141-27154
91. Masuoka H C., Mott J, Bronk S F. et al. Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem 2009 284 (44) 30039-30048
92. Cazanave S C., Gores G J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 2010 5 (1) 71-85
93. Witek R P., Stone W C., Karaca F G. et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009 50 (5) 1421-1430
94. Wieckowska A, Zein N N., Yerian L M., Lopez A R., McCullough A J., Feldstein A E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006 44 (1) 27-33
95. Younossi Z M., Jarrar M, Nugent C et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008 18 (11) 1430-1437
96. Malik R, Chang M, Bhaskar K et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009 24 (4) 564-568
97. Diab D L., Yerian L, Schauer P et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008 6 (11) 1249-1254
98. Horoz M, Bolukbas C, Bolukbas F F. et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol 2005 5 35
99. Chalasani N, Deeg M A., Crabb D W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004 99 (8) 1497-1502
100. Bonnefont-Rousselot D, Ratziu V, Giral P, Charlotte F, Beucler I, Poynard T, Lido Study Group. Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment Pharmacol Ther 2006 23 (1) 91-98
101. Mantena S K., King A L., Andringa K K., Eccleston H B., Bailey S M. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008 44 (7) 1259-1272
102. Videla L A., Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004 37 (9) 1499-1507
103. Higuchi H, Grambihler A, Canbay A, Bronk S F., Gores G J. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 2004 279 (1) 51-60
104. Gao D, Wei C, Chen L, Huang J, Yang S, Diehl A M. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2004 287 (5) G1070-G1077
105. Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005 22 (Suppl 2) 71-73
106. Bataller R, Brenner D A. Liver fibrosis. J Clin Invest 2005 115 (2) 209-218
107. Urtasun R, Nieto N. [Hepatic stellate cells and oxidative stress]. Rev Esp Enferm Dig 2007 99 (4) 223-230
108. Sanyal A J., Chalasani N, Kowdley K V. et al, NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010 362 (18) 1675-1685
109. Dryden G W. Jr, Deaciuc I, Arteel G, McClain C J. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep 2005 7 (4) 308-316
110. Di Sario A, Candelaresi C, Omenetti A, Benedetti A. Vitamin E in chronic liver diseases and liver fibrosis. Vitam Horm 2007 76 551-573
111. Chalasani N P., Sanyal A J., Kowdley K V. et al, NASH CRN Research Group. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009 30 (1) 88-96
112. Nobili V, Manco M, Devito R et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008 48 (1) 119-128
113. Feldstein A E., Lopez R, Abu-Rajab Tamimi T et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010 51 (10) 3046-3054